US$ 27.39
bpc 157 brain injury BPC-157 and the gut–brain axis: emerging links between cytoprotection and neuroregeneration The effect of pentadecapeptide BPC
Description
Commercialization for human therapeutic use remains prohibited in France, Europe, and the United States, hence the importance of sourcing strictly intended for in vitro and ex vivo research

However, long-term trials are necessary to conclude the clinical safety of this peptide
The recommendation to cycle off is based on caution, not hard evidence

Schedule your FREE consultation today!
